Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit ...
Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback